Definitive Healthcare Corp. filings document the regulatory disclosures of a public healthcare data and analytics software company. Recent Form 8-K reports furnish quarterly and annual financial-result releases covering revenue, net loss, adjusted profitability measures, cash flow, guidance, and impairment-related disclosures tied to the company’s subscription-based commercial intelligence platform.
The filing record also includes definitive proxy materials for annual stockholder matters, board elections, executive compensation, equity awards, and governance practices. Other material-event filings document board and committee composition changes, executive-role and compensation arrangements, and the termination of a nominating agreement affecting director-designation rights.
Definitive Healthcare Corp. (DH) is the subject of a Schedule 13D filed by a group of Advent International-affiliated funds disclosing significant ownership and a potential take-private proposal. The Advent entities report beneficial ownership of 62,493,676 shares of Class A common stock, representing 58.54% of outstanding shares, based on 106,744,713 shares outstanding as of August 6, 2026.
On September 1, 2026, Advent International, L.P., on behalf of various Advent funds, submitted a preliminary, non-binding indication of interest to a Special Committee of the Board to acquire all DH shares and AIDH TopCo, LLC units not already owned by Advent funds and founder Jason Krantz for an all-cash price of $1.02 per share (and an equivalent amount per OpCo unit). The Proposal assumes Mr. Krantz, the Executive Chairman and founder, rolls over his equity into the surviving company. The transaction would be subject to approval by the Special Committee and applicable regulators, and the Advent entities expressly reserve the right to modify or withdraw the Proposal; no binding obligation exists at this stage.
The filing notes that, as a result of the Proposal, Advent and Mr. Krantz may be deemed a “group” holding 84,991,654 shares, or 66.36% of the outstanding common stock. Advent also discloses existing arrangements: a Registration Rights Agreement granting customary registration rights; a Nominating Agreement giving director nomination rights while certain ownership thresholds (21.5% and 5%) are met; and a Voting Agreement under which Advent agrees to vote any “Excess Voting Securities” above 40.3% of DH’s voting securities in proportion to other stockholders.
Definitive Healthcare Corp. reported lower subscription-based revenue and a significantly larger loss for the six months ended June 30, 2026. Revenue was $111.1 million versus $119.9 million a year earlier, as subscription services fell to $106.4 million. The company posted a net loss of $199.8 million, driven largely by a non-cash $197.2 million goodwill impairment after sustained stock price declines, compared with a $164.4 million loss in the prior-year period.
Despite the loss, operating cash flow remained positive at $23.0 million, and cash and cash equivalents were $170.9 million with short-term investments of $12.7 million. Term loan debt totaled $161.9 million. The company reduced its Tax Receivable Agreement liability to $12.0 million and settled an acquisition earnout dispute for $7.5 million. It also executed a 2026 restructuring plan, incurring $1.1 million of severance-related charges, and impaired $0.2 million of lease right-of-use assets. Nasdaq notified the company on June 18, 2026 that its share price no longer met the $1.00 minimum bid requirement, starting a 180-day remediation period. Remaining performance obligations were $213.4 million, indicating contracted future revenue.
Definitive Healthcare Corp. reported second quarter 2026 revenue of $55.2 million, down from $60.8 million in Q2 2025. GAAP net loss narrowed to $7.5 million (14% of revenue) from $9.3 million (15% of revenue), while adjusted net income declined to $7.5 million from $9.7 million.
Adjusted EBITDA was $14.6 million, a 26% margin compared with $18.7 million and a 31% margin a year earlier. Cash flow from operations was strong at $11.5 million, and unlevered free cash flow was $11.6 million. Cash and cash equivalents rose to $170.9 million at June 30, 2026, with a term loan balance of about $160.6 million.
For Q3 2026, the company guides revenue to $54.0–$55.0 million and adjusted EBITDA of $13.5–$14.5 million (25–27% margin. For full year 2026, it expects revenue of $220.0–$222.0 million, adjusted EBITDA of $57.0–$59.0 million, and adjusted net income of $27.0–$29.0 million. Management highlighted improving net dollar retention, win-back momentum, and the launch of Turbo, an AI-powered healthcare intelligence platform.
Definitive Healthcare Corp. Executive Chairman and 10% owner Jason Ronald Krantz had 12,166 shares of Class A common stock withheld by the issuer on August 1, 2026 to satisfy tax obligations arising from the vesting and settlement of previously reported RSUs at $0.6823 per share.
Following this tax-withholding disposition, he directly holds 1,189,272 shares of Class A common stock and indirectly beneficially owns 450,000 shares through DH Holdings (formerly Jason R. Krantz 2009 Trust), of which he is the beneficiary.
Definitive Healthcare Corp. reported that Chief Financial Officer Casey Heller had 1,881 shares of Class A Common Stock withheld on August 1, 2026 to satisfy tax withholding obligations upon vesting of previously reported RSUs. After this tax-withholding disposition, Heller directly holds 1,839,595 shares.
Definitive Healthcare Corp. CEO Kevin Coop reported a tax-related share disposition tied to vested restricted stock units. On this Form 4, the issuer withheld 37,593 shares of Class A common stock at $0.80 per share to cover Coop’s tax withholding obligations upon RSU settlement. This was not an open-market sale, and after the withholding, Coop directly owns 4,975,229 shares of Class A common stock.
Definitive Healthcare Corp. reported that Chief Legal Officer Jonathan Paris had shares withheld to cover taxes tied to equity compensation. The issuer withheld 30,591 shares of Class A Common Stock at $0.80 per share to satisfy his tax withholding obligations upon vesting and settlement of previously reported RSUs. After this non-market tax-withholding disposition, Paris directly holds 872,263 shares of Class A Common Stock.
Definitive Healthcare Corp. has been notified by Nasdaq that its common stock no longer meets the $1.00 per share minimum bid price required for continued listing on the Nasdaq Global Select Market. The deficiency is based on 30 consecutive business days from May 6, 2026 to June 17, 2026.
The company has 180 calendar days, until December 15, 2026, to regain compliance. Nasdaq will deem the company compliant if the closing bid price is at least $1.00 per share for a minimum of ten consecutive business days, or longer if Nasdaq requires.
If the company does not regain compliance in this initial period, it may qualify for an additional 180-day period by meeting other Nasdaq Capital Market initial listing standards and potentially using actions such as a reverse stock split. The notice does not immediately affect trading, and the stock will continue to trade under the symbol DH while the company evaluates its options.
Hamood Samuel A reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. director Samuel A. Hamood received a grant of 189,190 restricted stock units, each representing one share of Class A Common Stock at no cash cost. These RSUs vest on the earlier of June 4, 2027 or the company’s next annual stockholder meeting, subject to his continued service.
Following this award, Hamood directly holds 289,396 Class A shares and has an additional 51,582 shares reported as indirectly held through AMHAM DH LLC.
Stephenson Scott G reported acquisition or exercise transactions in this Form 4 filing.
Definitive Healthcare Corp. reported that director Scott G. Stephenson received a grant of 189,190 shares of Class A Common Stock in the form of restricted stock units. Each RSU represents a contingent right to one share and will vest on the earlier of June 4, 2027 or the company’s next annual stockholder meeting, subject to his continued service. Following this award, Stephenson directly holds 313,314 shares of Class A Common Stock.